MARKETS LIVE
Loading markets…
Thursday, July 16, 2026 U.S. Edition
ASML Stock Drops 6% as Weak Bookings Shadow Earnings Beat
MRNA
Video MP4

ASML Stock Drops 6% as Weak Bookings Shadow Earnings Beat

MRNA Moderna, Inc. $65.50 -2.78 (-4.07%) Market Open $27.09T Mkt Cap -16.6 P/E Yield $85.60 52W High

Can ASML’s dominant position in AI chipmaking offset a worrying slowdown in traditional semiconductor demand?

How did ASML perform in Q2 2026?

During the second quarter of 2026, ASML reported total net sales of EUR 6.24 billion, which came in ahead of the consensus estimate of EUR 6.11 billion. The company’s net income reached EUR 1.58 billion, also surpassing the projected EUR 1.43 billion. Despite these seemingly strong figures, the market focused heavily on the underlying order intake. Net bookings for the quarter came in at EUR 5.57 billion, representing a significant decline compared to the EUR 7.12 billion reported in the same period last year. This sharp drop raised immediate red flags for analysts tracking the health of the broader technology market.

Why is the market reacting so negatively?

The primary source of concern for the market is the slower-than-expected recovery in traditional semiconductor sectors outside of artificial intelligence. While demand for high-end AI chips remains robust, consumer electronics, automotive, and industrial sectors are still struggling with high inventory levels. This imbalance is directly impacting ASML’s order pipeline. Furthermore, geopolitical tensions continue to cloud the company’s outlook. The U.S. government has been pressuring allies to tighten export restrictions on advanced chipmaking equipment to China. Since China has historically been a massive market for ASML, any further regulatory hurdles could severely impact future revenue streams.

What do major Wall Street analysts say?

Following the earnings release, several prominent financial institutions adjusted their outlook on the stock. Analysts at Citigroup noted that while the current quarterly figures are respectable, the weaker booking momentum could cap near-term stock performance. Meanwhile, JPMorgan Chase maintained its positive long-term view but acknowledged that geopolitical headwinds are creating temporary market uncertainty. RBC Capital Markets also pointed out that the semiconductor equipment sector might face a transition period as chipmakers digest their current capacity before committing to massive new capital expenditures.

How does this impact competitors and peers?

Conclusion

The negative sentiment surrounding ASML quickly spread to other major players in the semiconductor ecosystem. US-based rivals such as Applied Materials and Lam Research saw their stock prices slide during intraday trading. Even AI darling NVIDIA experienced temporary downward pressure as investors reassessed the valuation of the entire tech sector. This chain reaction highlights how interconnected the modern hardware market has become, where a guidance warning from a single European supplier can trigger a multi-billion-dollar sell-off on the NASDAQ.

Discussion
Loading comments...
VIEW FULL MRNA PROFILE →
Maik Kemper

Maik Kemper is the founder and editor-in-chief of Stock Newsroom. Active in the markets since the age of 18, he combines hands-on trading experience across forex, equities and cryptocurrencies with financial journalism. His focus: quarterly earnings analysis, corporate strategy, and macroeconomic trends.

More on MRNA — 60-Second Briefings

All MRNA →
MRNA

ASML Stock Drops 6% as Weak Bookings…

1h ago
MRNA

Moderna Forecast -8.2%: Plunge as $39 Target…

Jul 8, 2026
MRNA

Moderna Flu Vaccine -3.4% After FDA Panel…

Jul 7, 2026
MRNA

Moderna Strategy +13%: In Vivo CAR-T Surge…

Jun 26, 2026
MRNA

Moderna Flu Vaccine: FDA Briefing Sets Up…

Jun 17, 2026
MRNA

Moderna Restructuring +6.3% as FDA Momentum Builds

Jun 16, 2026
MRNA

Moderna Hantavirus +12% Rally: Can The Surge…

May 11, 2026
More on MRNA